4/7/2014 9:47:32 AM
NEW YORK--(BUSINESS WIRE)--Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced that it started a collaboration with IsoTherapeutics Group of Houston, TX to complete studies required for introduction of a new manufacturing process for Actimab-A. The new manufacturing process that results in a tenfold improvement of manufacturing yield has been developed by the Company internally in collaboration with IsoTherapeutics. IsoTherapeutics will perform additional experiments to generate documentation necessary for regulatory submissions.
Help employers find you! Check out all the jobs and post your resume.
comments powered by